Pure ingredients
Raw ingredients. Ancient wisdom. Modern results. Every product contains only what nature intended:
- Grass-fed tallow rich in bioavailable nutrients
- Raw honey and adaptogenic herbs in their purest form
- Regeneratively sourced proteins, never denatured
- Zero synthetic additives or lab-made fillers
Small-batch wellness our ancestors would recognize. Because when you honor nature's integrity, your body knows the difference.
Let customers speak for us
Why Purishh?
Pure Ingredients
Handpicked and ethically sourced from trusted, natural farms.
Effective Results
Each product is designed to protect, nourish, and enhance your skin’s natural balance.
Holistic Wellness
Embrace a balanced lifestyle with supplements and creams that work in harmony with your body.
Frequently Asked Question
What makes Purishh products different from conventional supplements or skincare?
What makes Purishh products different from conventional supplements or skincare?
Purishh’s mission is to return to the raw, unprocessed power of nature. Every product is formulated with 100 % natural ingredients and no synthetic preservatives, fillers, or dyes. For example, the Raw Honey Butter contains whipped Wagyu beef tallow, cold‑pressed olive and coconut oils, mango butter, raw honey and beeswax – it moisturizes deeply and can even replace conventional lotion. The Raw Tallow Sunbalm uses grass‑fed tallow, non‑nano zinc oxide and organic oils to provide mineral sun protection while nourishing the skin. Purishh’s Protein Powder combines grass‑fed whey and hydrolyzed collagen with organic superfoods to deliver 26 g of easily digestible protein with zero added sugar. Across their range, Purishh keeps ingredient lists short and transparent, using only what is necessary to support health and well‑being.
Are Purishh’s ingredients ethically and sustainably sourced?
Are Purishh’s ingredients ethically and sustainably sourced?
Yes. The founders emphasize sustainable sourcing and ethical treatment of animals and land. Tallow for the skincare range is hand‑sourced from 100 % grass‑fed, Wagyu, halal cattle in New Zealand, ensuring humane slaughter and optimal nutrient quality. Olive and coconut oils are single‑origin, cold‑pressed. The whey in Purishh protein powder comes from grass‑fed cows raised without hormones or antibiotics, and the collagen is hydrolyzed for better absorption. These practices mean customers receive products that are both pure and sustainable.
Why does Purishh use beef tallow in its skincare products?
Why does Purishh use beef tallow in its skincare products?
Grass‑fed beef tallow is biocompatible with human skin; its fatty‑acid profile closely resembles natural sebum, so it’s absorbed efficiently. Properly rendered tallow is a vitamin powerhouse, naturally supplying vitamins A, D, E, and K that support cell turnover, immune function, and antioxidant protection. Tallow also contains oleic, stearic and palmitic acids that strengthen the skin’s barrier, calm inflammation and maintain moisture. Grass‑fed tallow offers a high concentration of conjugated linoleic acid (CLA), an anti‑inflammatory fatty acid. These nutrients collectively help Purishh’s Raw Honey Butter and Raw Tallow Sunbalm to moisturize, nourish and protect the skin without clogging pores or causing irritation.
How is Purishh protein powder different, and why is it easy to digest?
How is Purishh protein powder different, and why is it easy to digest?
Many conventional protein powders use cheap sources and add artificial thickeners or sweeteners that cause bloating and digestive discomfort. Purishh starts with grass‑fed whey processed via cold‑filtration, which preserves natural enzymes and bioactive peptides that aid digestion. It also adds hydrolyzed bovine collagen to support joints, skin and gut health. The powder uses organic monk fruit for sweetness and contains no carrageenan, gums, sucralose or artificial preservatives, so it mixes smoothly and is gentle on the stomach. Each serving provides 26 g of complete protein with only 1 g of fat and zero sugar, making it suitable for keto, gluten‑free and non‑GMO diets.
What are Purishh Electrolytes, and how do they support hydration?
What are Purishh Electrolytes, and how do they support hydration?
Purishh’s Electrolytes formula offers clean hydration without the artificial colors and preservatives found in many sports drinks. Each serving includes over 800 mg of unrefined Himalayan salt, providing sodium and trace minerals, plus magnesium malate and potassium chloride. Organic fruit powders (raspberry or lemon‑lime) and monk fruit sweetener give a natural flavor without sugar. The formula helps replenish electrolytes lost through exercise, supports muscle function, and is keto‑friendly.
What is Raw Shilajit, and how should it be used?
What is Raw Shilajit, and how should it be used?
Raw Shilajit is a resin harvested from high‑altitude Himalayan rocks. It forms from decomposed plant material and is rich in minerals and fulvic acid. Traditionally used as an adaptogen, Shilajit helps boost energy, improve stamina and support overall health. Purishh provides 100 % pure Himalayan shilajit. Users typically dissolve a pea‑sized amount in warm water, tea or milk. Due to its potent minerals, start with a small dose and consult a healthcare professional if you have existing medical conditions.
What is the Ishh Leaky Gut Protocol?
What is the Ishh Leaky Gut Protocol?
The Ishh Leaky Gut Protocol is a step‑by‑step program designed to help restore gut health naturally. It includes dietary recommendations, lifestyle tips and natural supplements to support the intestinal lining. The protocol focuses on removing irritants, replenishing beneficial bacteria and repairing the gut barrier. It is not a medical treatment, so customers with chronic digestive issues should consult a healthcare professional before starting.
How should I store Purishh products?
How should I store Purishh products?
Store supplements and protein powders in a cool, dry place away from direct sunlight. Skincare products like Raw Honey Butter and Raw Tallow Sunbalm are natural and free from artificial stabilizers; keeping them at room temperature helps maintain texture. If you live in a hot climate, refrigerating tallow‑based balms can prevent melting. Always use clean hands or a spatula to avoid introducing bacteria.
When will my order ship, and how long will delivery take?
When will my order ship, and how long will delivery take?
Purishh asks customers to allow 2–3 business days for processing and production before an order ships. Once dispatched, average transit times are 7–10 business days; however, natural disasters, holidays and weather can cause delays. Free standard shipping is offered on orders over US$150 (or equivalent), and shipping costs for smaller orders are calculated at checkout. Purishh cannot guarantee exact delivery dates because delivery is ultimately the responsibility of the shipping carrier.
Can I subscribe and save on regular purchases?
Can I subscribe and save on regular purchases?
Yes. Purishh offers a subscription program for products like protein powder. Subscribing gives 10 % off the regular price, and you can choose delivery intervals (e.g., monthly). Subscriptions auto‑renew, but you may skip or cancel at any time through your account.
Are Purishh products allergen‑free or suitable for special diets?
Are Purishh products allergen‑free or suitable for special diets?
Purishh formulates products without common synthetic additives, but some items may contain potential allergens. The protein powder contains whey (a dairy product) and collagen derived from bovine sources; it is unsuitable for vegans or those with dairy allergies. The Electrolytes formula is gluten‑free, sugar‑free and keto‑friendly. Always review ingredient lists carefully and consult your healthcare provider if you have specific allergies or dietary restrictions.
Where are Purishh products made?
Where are Purishh products made?
Purishh sources ingredients globally, such as New Zealand Wagyu tallow and Himalayan shilajit, but manufactures products in small batches under rigorous quality control. By keeping production small and hands‑on, Purishh can maintain freshness and ensure every batch meets the highest standards.
Pür Insights
Creatine and Cognitive Function: What the Newest Research Shows
Creatine and Cognitive Function: What the Newest Research Shows Creatine's reputation has expanded rapidly over the past few years from a well-established muscle supplement into something marketed as a brain supplement, and the shift happened faster than the evidence did. The actual research picture here is one of the more instructive cases in nutrition science right now, not because the answer is simple in either direction, but because it involves a widely publicized positive meta-analysis, a serious published statistical challenge to that meta-analysis, a second meta-analysis facing the same criticism, and a formal regulatory assessment that reached a conclusion most consumers have never heard. It's also a case where one of the researchers behind the positive findings has said publicly that it's too early to draw the conclusion his own work is frequently cited to support. That's worth taking seriously. The mechanism is real, and worth understanding first The biological rationale connecting creatine to cognition isn't invented marketing. It rests on genuine, well-documented brain physiology. The brain is metabolically expensive. Despite representing a small fraction of body weight, it consumes a disproportionate share of the body's energy, and that energy is delivered as adenosine triphosphate, or ATP. Creatine's central biological role, the same one that underlies its muscle benefits, is participating in the phosphocreatine system, which allows rapid regeneration of ATP from ADP during periods of high demand. This system operates in brain tissue as well as muscle, and creatine kinase, the enzyme driving it, is present in tissues with high and fluctuating energy demands, which describes the brain accurately. From there, the hypothesis is straightforward: if supplementation can increase brain creatine stores, and if brain energy availability constrains cognitive performance under certain conditions, then supplementation might improve cognitive performance, particularly under conditions of metabolic stress. That's a coherent chain of reasoning, and it's why serious researchers have pursued this question rather than dismissing it. The critical qualifier is that each link in that chain requires evidence, and the evidence weakens considerably as you move along it. Notably, research examining whether short-term supplementation actually raises brain creatine content has produced mixed results, with at least one study finding that a seven-day protocol did not elicit improvements in brain creatine content or cognitive performance in healthy young people, suggesting this population may rely primarily on the brain's own creatine synthesis rather than dietary or supplemental intake to maintain brain creatine levels. The meta-analysis that drove the popular claim Most of the confident public messaging about creatine and cognition traces back to a specific 2023 paper: Prokopidis, Giannos, Triantafyllidis, Kechagias, Forbes, and Candow, "Effects of creatine supplementation on memory in healthy individuals: a systematic review and meta-analysis of randomized controlled trials," published in Nutrition Reviews, volume 81, issue 4, pages 416 to 427. The methodology was reasonable on its face. The authors searched PubMed, Web of Science, the Cochrane Library, and Scopus from inception through September 2021, identified 23 eligible randomized controlled trials, narrowed to 10 meeting inclusion criteria for the systematic review, and included 8 in the meta-analysis itself. The headline result: creatine supplementation improved measures of memory compared with placebo, with a standardized mean difference of 0.29, a 95 percent confidence interval of 0.04 to 0.53, heterogeneity of 66 percent, and a p-value of 0.02. The authors concluded that creatine enhanced memory performance in healthy individuals, especially in older adults aged 66 to 76. Those specific numbers deserve a closer read than they usually get. A standardized mean difference of 0.29 is a small effect by conventional interpretation. The confidence interval's lower bound of 0.04 sits very close to zero, meaning the finding is statistically significant but only barely, and a modest shift in the underlying data could move it to non-significance. And an I-squared value of 66 percent indicates substantial heterogeneity, meaning the individual studies pooled together disagreed with each other considerably, which weakens confidence that they're all measuring the same underlying effect. None of that makes the paper wrong. It makes the finding modest and fragile rather than robust, which is a meaningfully different thing than how it's typically represented. The statistical challenge Later in 2023, Nutrition Reviews published a letter to the editor by Eckert and Pascher, in volume 81, issue 11, pages 1495 to 1496, titled directly: "Double-counting due to inadequate statistics leads to false-positive findings." Their criticism concerns a specific and consequential methodological problem. Several of the individual studies included in the meta-analysis reported multiple memory subtests from the same participants. When each of those subtests is entered into a pooled analysis as if it were an independent observation, the total number of observations exceeds the number of unique randomized participants. This violates the statistical assumption that observations are independent of one another, and the documented consequence is that it artificially inflates precision and statistical power, which increases the risk of a false-positive finding. The authors of the original meta-analysis published a reply, and the exchange is available in the same journal for anyone wanting to evaluate both positions directly rather than taking either side's characterization on faith. What matters for a reader trying to assess this evidence is that the central positive finding driving most public claims about creatine and memory has faced a specific, published, methodological challenge from other researchers, and that challenge concerns the statistical foundation of the result rather than a matter of interpretation. The second meta-analysis, and the same problem A subsequent meta-analysis by Xu, Bi, Zhang, and Luo, "The effects of creatine supplementation on cognitive function in adults," was published in Frontiers in Nutrition in July 2024, volume 11, article 1424972, following PRISMA 2020 guidelines and covering randomized controlled trials published between 1993 and 2024. Two things happened to this paper worth knowing about. First, it required a formal corrigendum, published in Frontiers in Nutrition in February 2025, correcting an error in the results section on attention that the authors attributed to a translation error from Chinese to English. Corrigenda are a normal and healthy part of scientific publishing, and their existence isn't itself damning, but a correction to a results section is more consequential than a typographical fix. Second, and more substantively, a commentary published in Frontiers in Nutrition in 2026 by Citherlet raised the same double-counting criticism against this meta-analysis that Eckert and Pascher raised against Prokopidis. The commentary identified specific examples: in the memory analysis, the Alves 2013 studies each contributed at least seven memory subtests, McMorris 2006 contributed four, McMorris 2007b four, and Pires 2020 four, meaning the number of pooled observations again exceeded the number of unique randomized participants. So the two most cited meta-analyses supporting creatine's cognitive benefits have both faced published criticism for the same specific statistical problem, from independent commentators, in peer-reviewed venues. The regulatory assessment almost nobody cites In November 2024, the European Food Safety Authority's Panel on Nutrition, Novel Foods and Food Allergens published a formal scientific opinion evaluating a health claim application linking creatine supplementation to improved cognitive function. The opinion appears in the EFSA Journal, volume 22, issue 11, article e9100, authored by Turck and colleagues. The application had been filed by Alzchem Trostberg GmbH, a major creatine manufacturer, through Austria's competent authority. This matters because a regulatory health claim evaluation is a different kind of exercise than a meta-analysis. The applicant has a direct commercial incentive to present the strongest available case, submits the evidence they consider most compelling, and can respond to additional data requests, which EFSA issued twice during this evaluation. The panel then assesses whether the totality of that evidence establishes a cause-and-effect relationship. The panel evaluated 21 human intervention studies identified by the applicant, plus two additional studies identified through a meta-analysis reference list, plus a systematic review and meta-analysis of 16 randomized controlled trials submitted in response to an additional data request. Their conclusion, stated directly: a cause-and-effect relationship has not been established between creatine supplementation and an improvement in cognitive function in one or more of its domains. What EFSA specifically found The reasoning behind that conclusion is more informative than the conclusion alone. On dosing, the panel noted that acute effects on working memory were observed at daily doses of 20 grams per day, but these effects were not observed at lower doses, nor with continuous supplementation at 5 grams per day for six weeks. This is a genuinely important detail. Twenty grams per day is a loading-phase dose, roughly four times the standard maintenance dose most people take, and the effects that appeared at that level did not persist at the doses actually used in typical daily supplementation. On consistency, the panel observed that an effect on response inhibition at 20 grams per day for seven days was an isolated finding among ten intervention studies in healthy individuals, with no effects observed on other cognitive domains. A single positive result across ten studies, in one domain only, is the kind of pattern that could easily reflect chance rather than a genuine effect. On clinical populations, the three intervention studies conducted in diseased individuals did not support an effect of creatine supplementation on cognition. On mechanism, the panel considered the available evidence for a mechanism by which creatine could exert the claimed effect to be weak, notwithstanding the plausible theoretical reasoning described earlier in this post. The panel also revisited three older studies, McMorris 2006, McMorris 2007, and Rae 2003, which it had previously evaluated in a 2011 opinion on creatine and memory. Its assessment of their methodological quality was blunt: lack of information on randomization procedures, inadequate adjustment for baseline differences, multiple uncorrected pairwise comparisons or an inappropriate significance level, and insufficient detail on the statistical models used to allow scientific assessment. The panel concluded no conclusions could be drawn from those studies for substantiating the claim. Notably, several of those same studies appear in the meta-analyses discussed above. The practical consequence is that health claims linking creatine to cognitive benefits cannot be used on products marketed in the European Union. What a researcher behind the positive findings said The most striking element of this whole picture comes from Darren Candow, a co-author on the Prokopidis meta-analysis and one of the more prolific creatine researchers working today. Responding to the EFSA decision, Candow said it was justified based on the current body of research, which he described as very small. He noted that when you look closely at the studies, most of the results relate to a metabolic stressor, or the dosages used were very inconsistent. He also pointed out that no study has given creatine to individuals and then measured whether cognition remained improved after creatine withdrawal, that individual studies are underpowered, that current meta-analyses are inconsistent, and that no dosing studies using magnetic resonance spectroscopy have been performed. His summary: in his opinion, it's way too early to conclude that creatine improves cognition overall. When a researcher who co-authored a positive meta-analysis publicly agrees that a regulator was right to reject the claim his work is cited to support, that's about as clear a signal as this field produces about where the evidence actually stands. Where the signals, such as they are, appear strongest None of this means the hypothesis is dead, and the honest version includes where the more promising signals cluster. Older adults appear repeatedly as the population where effects, when detected, are most often found, which is consistent with the Prokopidis finding specifically highlighting adults aged 66 to 76. A systematic review of creatine and cognition in aging published in Nutrition Reviews in 2026 continues examining this population specifically, while noting contradictory findings across the literature and the need for further clinical studies exploring mechanism. Vegetarians are a mechanistically interesting group, since dietary creatine comes primarily from meat and fish, meaning vegetarians typically have lower baseline creatine stores and therefore more theoretical room for supplementation to matter. Research by Rae and colleagues in 45 young adult vegetarian participants reported positive effects on working memory and intelligence measures, though this study is among those EFSA specifically criticized on methodological grounds. Conditions of metabolic stress, particularly sleep deprivation, recur as a context where effects have been observed, consistent with Candow's observation that most positive results relate to a metabolic stressor rather than to baseline cognitive performance in rested, well-nourished individuals. The pattern suggests that if creatine does affect cognition, it may do so specifically by relieving a constraint in people who have one, whether from age, diet, or acute stress, rather than by enhancing performance in people who don't. That's a considerably narrower claim than "creatine improves brain function," and it's still not established. The contrast worth drawing There's a useful comparison sitting right next to this one. In 2016, EFSA approved an Article 13(5) health claim for creatine in combination with resistance training to improve muscle strength in adults over the age of 55. Same regulator, same evidentiary standard, same compound, entirely different outcome. That contrast is the most useful thing to take from all of this. Creatine's effects on muscle performance and strength are supported by decades of consistent research and have cleared one of the more demanding regulatory bars in the world. Its effects on cognition rest on a smaller body of literature, with two prominent meta-analyses facing published statistical criticism, isolated findings at loading doses that don't persist at normal doses, and a formal regulatory determination that causation has not been established. Both facts are about the same supplement. Holding them simultaneously, rather than letting the strength of one carry the other, is what accuracy requires here. The honest summary The mechanism connecting creatine to brain energy metabolism is real and plausible. The clinical evidence that supplementation improves cognitive function in healthy adults at typical doses is weak, contested, and formally judged insufficient to establish causation by EFSA in November 2024 after reviewing 21 human intervention studies. The two most-cited meta-analyses supporting cognitive benefits have both been challenged in peer-reviewed commentary for double-counting non-independent outcomes, a statistical problem known to inflate false-positive findings. One of the authors of the more prominent of those meta-analyses has publicly stated it's too early to conclude creatine improves cognition. If you take creatine, the reasons to do so remain well supported: strength, power output, recovery, and lean mass maintenance, particularly with resistance training and particularly as you age. Cognitive benefit is an interesting hypothesis with some suggestive signals in specific populations, not an established outcome, and anyone telling you otherwise is ahead of the evidence. That may change. Larger, better-powered trials with proper statistical handling, MRS-based dosing studies, and research specifically designed around the populations where signals cluster could all shift this picture. Until they do, the accurate answer is that this remains an open question, and the newest research has made the case weaker rather than stronger.
Learn moreWhat Heavy Metal Testing Actually Catches (and Why Most Brands Don't Publish It)
What Heavy Metal Testing Actually Catches (and Why Most Brands Don't Publish It) Heavy metal testing is the single most important verification available for a dietary supplement, and it's also one of the least frequently published. That combination isn't an accident, and the reasons behind it are worth understanding in detail, because they explain something important about how to read the supplement market generally: the absence of a document isn't always evidence of a problem, but it does mean a question that could have been answered definitively simply wasn't. This post covers what heavy metal testing actually measures, how the analytical methods work and where their real limits sit, what standards exist and which are genuinely binding, and the specific structural reasons publication remains voluntary and uncommon. The four metals, and why these four Heavy metal testing in dietary supplements almost universally focuses on four elements: lead, arsenic, cadmium, and mercury. These are classified as Class 1 elemental impurities under the relevant pharmaceutical standards, a designation reserved for elements considered human toxicants with no established beneficial biological role, which are generally restricted or prohibited in the manufacturing process. The reason these four dominate testing isn't arbitrary. They share a specific combination of properties that makes them uniquely relevant: they occur naturally in soil and water, meaning plants absorb them during normal growth without any contamination event occurring; they accumulate in the body rather than being efficiently cleared; and they have well-documented toxicity at chronic low-level exposure, not just at acute high doses. That last point matters especially for supplements, since a supplement is by definition something taken repeatedly over long periods, which is precisely the exposure pattern where cumulative low-level intake becomes relevant. How the testing actually works The analytical method that matters most here is inductively coupled plasma mass spectrometry, universally abbreviated ICP-MS, and understanding roughly how it works helps explain both its power and its limitations. A sample is first digested, typically in strong acid, to break down the organic matrix and release any metals present into solution. That solution is then introduced into an argon plasma operating at extremely high temperature, which atomizes and ionizes the elements present. Those ions are then separated by their mass-to-charge ratio in a mass spectrometer and counted. Because different elements have different atomic masses, the instrument can distinguish and quantify each element in the sample simultaneously. The sensitivity involved is genuinely remarkable and worth stating concretely. Under the standards governing this testing, ICP-MS is expected to reliably detect elemental impurities at concentrations in the range of nanograms per milliliter, with some applications requiring detection limits as low as 0.01 nanograms per milliliter, a level that remains comfortably within the technique's capability. For perspective, that's a sensitivity level capable of detecting quantities that would be entirely invisible to any less sophisticated method, which is precisely why it replaced older approaches. That replacement is worth knowing about specifically, because it explains why testing standards changed relatively recently. USP General Chapter 231, the older "Heavy Metals" chapter that governed this area for decades, was determined to be obsolete and was eliminated entirely as of January 1, 2018. It was replaced by a set of modern chapters: General Chapter 232, Elemental Impurities Limits, General Chapter 233, Elemental Impurities Procedures, and General Chapter 2232, Elemental Contaminants in Dietary Supplements. The older method relied on a colorimetric approach that was considerably less sensitive and less specific than modern instrumental analysis, meaning testing conducted under the old standard could genuinely miss contamination that current methods would catch. Any COA referencing the obsolete USP 231 method rather than current chapters is therefore working from a standard that was formally retired, which is a reasonable thing to notice. The limits, and an important detail about how they're expressed USP General Chapter 232 establishes permitted daily exposure values, commonly abbreviated PDE, for 24 elemental impurities, classified by both potential toxicity and route of administration. Here's a detail that changes how these numbers should be read, and it's genuinely important: PDE limits are daily exposure limits, not concentration limits in a raw material. This distinction has real practical consequences. If a supplement delivers 1,500 milligrams of a botanical extract per day across three capsules, the raw material specification for lead has to be tight enough that the total daily dose stays under the applicable exposure limit, which means the acceptable concentration in the raw material depends entirely on how much of that material a person actually consumes daily. A raw material concentration that would be perfectly acceptable in a product taken at 200 milligrams daily could exceed exposure limits in a product taken at 2,000 milligrams daily, from identical starting material. This is why simply comparing a parts-per-million number on one COA against a parts-per-million number on another, without accounting for serving size, can be genuinely misleading. The meaningful question is always total daily exposure at the recommended serving, not concentration in isolation. The voluntary nature of all of this Here's the structural fact that explains most of why publication is uncommon: USP chapters 232 and 233 were written for pharmaceutical products. Dietary supplement manufacturers frequently adopt the same framework voluntarily to demonstrate product quality, and USP 2232 exists specifically to address elemental contaminants in dietary supplements, but adopting these standards is a choice a manufacturer makes rather than a binding requirement enforced through pre-market review. This follows directly from how dietary supplements are regulated in the US generally. Under the Dietary Supplement Health and Education Act of 1994, supplements are classified as a category of food rather than drugs and do not require pre-market approval. Nobody independently verifies a supplement's contents before it reaches a shelf, which means whether heavy metal testing happens at all, at what rigor, using which method, against which limits, and whether the results are ever shown to anyone outside the company, are all decisions the manufacturer makes internally. Good Manufacturing Practice regulations, which are mandatory and enforced through FDA inspection, require manufacturers to establish specifications and verify that products meet them, which does create real accountability. But GMP compliance is about having and following a documented process, not about publishing the resulting data. A GMP-compliant manufacturer can run rigorous heavy metal testing on every batch, meet every specification, and share none of it publicly, entirely within the rules. Why brands don't publish, in order of how honest each reason is There are several genuinely different reasons a brand might not publish heavy metal testing, and they're worth separating rather than collapsing into a single cynical assumption. The most benign explanation is that they simply haven't been asked enough to build the process. Publishing batch-specific COAs requires ongoing operational work: getting results from the lab, formatting them for public consumption, updating them as new batches are produced, and maintaining a system where a customer can match the lot number on their bottle to the right document. For a brand not receiving many requests, this is real work with no obvious return, and its absence reflects priorities rather than concealment. A more substantive reason involves the labs themselves. Testing laboratory reports commonly include language stating the report may not be reproduced, or used in advertising or the sale of any product, without written authorization from the laboratory. This is standard practice protecting the lab from having its name attached to marketing claims it didn't review or endorse. It means a brand generally can't simply post a raw lab PDF as a marketing asset without addressing that permission question, which is part of why summarizing results is more common than publishing complete documents. A third reason is genuinely about the documents themselves. Many COAs contain information a brand reasonably considers commercially sensitive, including supplier identities, exact formulation details, and manufacturing partner names. Publishing an unredacted COA reveals supply chain relationships that competitors would find useful. And then there's the least charitable explanation, which is real often enough to warrant mentioning: some brands haven't done the testing at all, or have done it once on a single batch years ago, or have received results they'd rather not display. In a category where nobody checks before a product ships and publication is entirely optional, this is a structurally available choice, and it's precisely why the absence of documentation, while not proof of a problem, is worth noticing as an unanswered question rather than assumed away. What testing genuinely can't tell you This is worth being clear about, because overstating what a clean COA proves is its own form of misleading. A heavy metal test describes the specific sample that was analyzed, from the specific batch it was drawn from, on the specific date it was run. It doesn't describe the batch produced three months later from a different raw material shipment. This is the entire reason batch-specific documentation matters more than a single certificate published once and left indefinitely. Testing is also sampling, not exhaustive verification. A sample drawn from a batch is assumed representative of the whole, which is a reasonable statistical assumption for a well-blended finished product, but it's an assumption rather than a guarantee, particularly for products where mixing may be less uniform. A heavy metal panel also only covers the elements actually tested. A standard four-element panel says nothing about pesticide residues, microbial contamination, solvent residues from extraction processes, or whether the product contains what its label claims. These are separate analyses answering separate questions, and a brand pointing to a heavy metal COA when asked about potency is answering a different question than the one being asked. And detection limits, while extremely low with modern ICP-MS, are not zero. A result reported as "not detected" means below the method's detection limit for that element, which is a meaningfully different statement than absolute absence. A well-constructed COA states the detection limit alongside the result, which is a small detail worth looking for. What a genuinely useful COA looks like Pulling this together into what's actually worth checking when you do get a document. It should name the testing laboratory and, ideally, its accreditation, with ISO/IEC 17025 being the recognized standard for laboratory competence. It should reference a batch or lot number matching the product in hand. It should name the analytical method, with ICP-MS being the expected modern standard, and reference current USP chapters rather than the retired 231. It should report numeric results for each of the four metals individually rather than a combined figure or a bare pass mark, alongside the specification or limit those results are being measured against, and ideally the detection limit for results reported as not detected. A document meeting all of these is doing something genuinely meaningful. One missing several of them may still reflect real testing, but it's providing less verifiable information than it appears to. The honest summary Heavy metal testing via ICP-MS is a mature, extremely sensitive analytical method capable of detecting contamination at concentrations far below any level of practical concern, governed by a modern standards framework that replaced a genuinely obsolete method as recently as 2018. The limits that framework establishes are daily exposure limits rather than raw concentration limits, which means serving size matters as much as the number on the page. None of this framework is mandatory for dietary supplements in the way it is for pharmaceuticals, and publication of results is entirely voluntary regardless of what testing was performed. Reasons for not publishing range from genuinely benign operational and legal constraints to the simple absence of testing altogether, and from the outside, these look identical. That's precisely why asking for a batch-specific document, rather than accepting a general assurance, is the single most useful thing a person can do when evaluating a supplement's safety, and why a brand's willingness and ability to produce one quickly tells you something meaningful that no amount of clean-sounding label language can substitute for.
Learn moreRaw Honey for Skin: What the Research Actually Supports
Raw Honey for Skin: What the Research Actually Supports Honey shows up in an enormous range of skincare products, from luxury masks to drugstore cleansers to DIY recipes circulating on social media, and the claims attached to it range from reasonable to wildly overstated. The actual dermatological research is genuinely more interesting than either the marketing or the skepticism, because it includes real clinical trials with real, measurable results, alongside significant limitations that most content citing those trials leaves out entirely. We've written separately about honey's antibacterial mechanisms and where that evidence is strongest, primarily wound care. This post covers something different: what the research specifically supports for skin as a cosmetic and dermatological application, what the clinical trials actually measured, and where the honest boundaries of that evidence sit. The humectant mechanism, which is the least controversial thing about honey and skin The most straightforward, least disputed property honey brings to skin is that it's an effective humectant, meaning it attracts and binds water. This isn't a marketing claim requiring careful evaluation. It's a straightforward consequence of honey's composition. Honey is roughly 80 percent sugars, primarily fructose and glucose, and sugars are hygroscopic, meaning they naturally draw and hold water molecules. In dermatological terms, humectants are one of three recognized categories of moisturizing ingredients, alongside occlusives, which form a physical barrier reducing water evaporation, and emollients, which fill microscopic gaps between skin cells to improve texture and smoothness. Glycerin, urea, and hyaluronic acid are the humectants most commonly used in commercial skincare, and honey functions through the same basic mechanism. There's a genuine caveat worth understanding about all humectants, not specific to honey, that gets left out of most product marketing. Humectants draw water from wherever it's available. In high ambient humidity, above roughly 70 percent, they can draw moisture from the air. In dry conditions, they more commonly draw water from the deeper layers of your own epidermis, which can, without a concurrent occlusive ingredient sealing that moisture in, actually increase transepidermal water loss and worsen dryness rather than improving it. This is well documented in clinical dermatology references and it's a real, mechanistic reason why humectants generally work better as part of a formulation that also includes an occlusive or emollient component than they do applied entirely on their own in a dry environment. The atopic dermatitis research: real, promising, and genuinely limited This is where honey's skin research gets specific enough to be worth examining closely, and where the difference between what a study found and how it gets cited becomes important. A 2017 study by Abdullah Alangari and colleagues at King Saud University, published in Immunity, Inflammation and Disease, investigated Manuka honey for atopic dermatitis using an elegant study design: participants with bilateral lesions, meaning matching lesions on both sides of the body, applied Manuka honey to one site overnight for seven consecutive days while leaving the contralateral lesion untreated as a within-person control. Severity was assessed using the Three Item Severity score, a validated clinical measure. The results were meaningful. Honey-treated lesions showed a statistically significant improvement, with a mean difference of negative 2 points and a p-value below 0.001, while untreated control lesions showed no statistically significant change, with a mean difference of negative 0.7 points and a p-value of 0.15. The treatment was well tolerated, with none of the participants who completed the study reporting adverse events. The study also included laboratory work investigating why this might happen, which is worth understanding because it moves beyond simple observation. Manuka honey significantly downregulated IL-4-induced CCL26 release from HaCaT cells, a human keratinocyte line, in a dose-dependent manner. CCL26, also called eotaxin-3, is a chemokine involved in recruiting inflammatory cells in allergic skin conditions. The researchers also found that mast cell degranulation was significantly inhibited following honey treatment. Separately, this connects to a well-documented feature of atopic dermatitis: Staphylococcus aureus colonizes the skin of the large majority of people with the condition, and a systematic review pooling data across 95 observational studies found that people with atopic dermatitis had dramatically higher odds of S. aureus colonization compared to healthy controls, with a pooled odds ratio of 19.74. Honey's documented anti-staphylococcal activity offers a plausible second mechanism alongside the anti-inflammatory pathway. Now the limitations, which matter enormously and which the researchers themselves stated clearly. This was an open-label pilot study, not a randomized controlled trial. It enrolled 16 participants, of whom two withdrew due to worsening symptoms, leaving 14 completers. There was no placebo or vehicle control, meaning the comparison was honey versus nothing rather than honey versus an inactive substance that would control for the effects of simply applying something occlusive and moist to a lesion overnight. The authors' own stated conclusion was that honey is "potentially effective" and that this "needs to be confirmed by randomized and controlled clinical trials," a genuinely appropriate level of caution that gets stripped away in most secondary coverage of this study. It's also worth noting explicitly that two of sixteen participants withdrew because their symptoms worsened. That's a small number in a small study, and it may or may not have been related to the honey itself, but it's a real detail from the actual data that deserves inclusion rather than omission when discussing tolerability. What this means practically, and where the boundary sits The atopic dermatitis findings are genuinely encouraging and mechanistically coherent, which is a meaningful combination. It's not just an observed effect with no plausible explanation, nor is it a plausible mechanism with no clinical observation. Both exist, which is more than can be said for many ingredients marketed for skin. What it isn't, is established treatment. Atopic dermatitis is a genuine medical condition, and a 14-person open-label pilot study, however well-designed within its constraints, doesn't establish honey as a treatment for it. Anyone managing atopic dermatitis should be working with a dermatologist rather than substituting a supplement or cosmetic product for medical care, and this post isn't suggesting otherwise. The research is worth knowing about precisely because it's real and specific, not because it changes what appropriate care for a diagnosed skin condition looks like. This is also a good place to be precise about a distinction that matters for the entire category. Most of the encouraging clinical research on honey and skin uses medical-grade honey, which is gamma-irradiated to sterilize it while preserving its active compounds, and typically Manuka specifically, which contains methylglyoxal at concentrations far above other honey varieties and derives much of its documented antibacterial activity from that compound rather than from the hydrogen peroxide pathway most other raw honeys rely on. Retail raw honey, however high quality, is not medical-grade honey and is not typically Manuka. The mechanisms overlap meaningfully but they're not identical, and extrapolating clinical results from a specific medical-grade Manuka preparation directly to any raw honey in a cosmetic formulation is a stretch worth naming rather than glossing over. The antioxidant and phenolic content angle Raw honey contains phenolic compounds and flavonoids, and their concentrations vary considerably based on floral source, which is why different honey varieties test differently for antioxidant activity in laboratory settings. Buckwheat honey, for instance, consistently tests higher in phenolic content than lighter varieties like clover. The reasonable version of what this supports: these compounds have documented antioxidant activity in laboratory testing, and antioxidant activity in skin is a legitimate area of dermatological interest, since oxidative stress from UV exposure and environmental factors contributes to skin aging processes. The less reasonable version, which appears frequently in marketing, is the leap from "contains antioxidant compounds" directly to "reverses skin aging" or similar claims. That leap requires clinical evidence in humans measuring actual skin outcomes, which for honey specifically as a topical antioxidant is considerably thinner than the laboratory data on the compounds themselves. A useful way to hold this: the antioxidant content is real and measurable, the mechanism by which antioxidants could benefit skin is scientifically legitimate, and the specific clinical evidence that topically applied honey produces measurable anti-aging outcomes in humans is not well established. All three of those statements are true simultaneously. Acne: where the evidence is weakest Honey appears frequently in DIY acne remedies and in some commercial acne products, and this is the application where the evidence is thinnest relative to how confidently it's promoted. The theoretical rationale isn't unreasonable. Acne involves bacterial colonization by Cutibacterium acnes alongside inflammation, and honey has documented antibacterial and anti-inflammatory properties. But rationale isn't evidence, and rigorous clinical trials specifically testing honey for acne with meaningful sample sizes and appropriate controls are largely absent from the literature. What exists tends to be small, poorly controlled, or focused on honey as one component of a multi-ingredient preparation, which makes attributing any observed effect to honey specifically difficult. There's also a practical consideration specific to acne-prone skin worth raising honestly: honey is sugar-dense, and while it doesn't feed C. acnes in the way sometimes claimed, applying a sticky, sugar-rich substance to acne-prone facial skin and leaving it in prolonged contact isn't obviously beneficial, and individual responses vary. Anyone with acne-prone skin trying honey topically would be sensible to patch test rather than assume it's universally well tolerated, the same general caution we've applied to other ingredients in this series. What this supports for cosmetic formulations specifically Bringing this back to the practical question of honey as an ingredient in a rinse-off or leave-on cosmetic product, rather than as a standalone therapeutic application. In a formulation, honey's most defensible contribution is its humectant function, drawing and binding moisture, which is well established and doesn't require any of the more ambitious clinical claims to be true. Its antibacterial properties contribute meaningfully to a formulation's overall character, and in some cases to preservation, though contact time in a rinse-off product is far too brief for the wound-care-level antibacterial activity documented in clinical research to be the relevant mechanism. The phenolic and antioxidant content is a genuine part of what raw honey brings compared to heavily processed honey, with the caveat about clinical outcomes noted above. What honey in a cosmetic formulation is not doing is delivering the therapeutic effects documented in the medical-grade Manuka atopic dermatitis research. Different preparation, different honey variety, different concentration, different contact time, different application context. The research is interesting and real, and it applies to a specific set of conditions that a soap or conditioner formulation doesn't replicate. The honest summary Raw honey's best-supported property for skin is its function as a humectant, which is mechanistically straightforward and not seriously disputed, with the general caveat that humectants work best alongside occlusive or emollient ingredients rather than in isolation, particularly in dry conditions. The most compelling clinical research on honey and a specific skin condition comes from a 2017 pilot study on Manuka honey for atopic dermatitis, which found statistically significant improvement in treated lesions alongside plausible anti-inflammatory and anti-staphylococcal mechanisms, and which was explicitly limited by its small size, open-label design, and lack of a vehicle control, limitations the study's own authors clearly stated. The antioxidant content is real, the mechanism is legitimate, and the human clinical outcome data specifically for topically applied honey is thin. The acne evidence is the weakest of the applications commonly promoted. And medical-grade Manuka honey used in clinical research is meaningfully different from retail raw honey in a cosmetic product, a distinction worth maintaining rather than blurring. That's a more qualified picture than most honey skincare content offers, and it's the one the actual research supports.
Learn more


